|
|
|
| |
|
|
| |
|
|
| |
We are currently working on two controlled release systems that offer medication at desired levels over a longer period, thus offering better blood levels and control over symptoms. |
|
|
|
|
| |
The two different types of controlled release systems we are working on are: |
|
|
|
|
|
 |
|
|
|
|
|
Sun Pharma has licensed in the Wrap matrix technology for one of the devices to file an ANDA with the USFDA for a bioequivalent tablet formulation of Wyeth's Effexor XR, which is available as a capsule. Wyeth has granted Sun Pharma a “will-not-sue” covenant for this product, cutting short the route to market, litigation costs and uncertainty. The approval by the USFDA is expected after the base patent expires in June 2008. SPARC would earn a technology fee and a stepped royalty from the sales of this product when Sun Pharma's generic Effexor XR reaches market. |
|
|
Next » |
|
|
|
|
|
